Free Trial

Microbix Biosystems (MBX) Competitors

Microbix Biosystems logo
C$0.23 -0.01 (-2.13%)
As of 08/22/2025 03:59 PM Eastern

MBX vs. ONC, SCYB, COM, NVH, IGX, MDNA, HBP, PDP, COV, and APS

Should you be buying Microbix Biosystems stock or one of its competitors? The main competitors of Microbix Biosystems include Oncolytics Biotech (ONC), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Medicenna Therapeutics (MDNA), Helix BioPharma (HBP), Pediapharm (PDP), Covalon Technologies (COV), and Aptose Biosciences (APS). These companies are all part of the "biotechnology" industry.

Microbix Biosystems vs. Its Competitors

Oncolytics Biotech (TSE:ONC) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Microbix Biosystems has a net margin of 13.86% compared to Oncolytics Biotech's net margin of 0.00%. Microbix Biosystems' return on equity of 12.65% beat Oncolytics Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncolytics BiotechN/A -141.94% -71.33%
Microbix Biosystems 13.86%12.65%3.82%

Oncolytics Biotech presently has a consensus target price of C$3.50, indicating a potential upside of 146.48%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Oncolytics Biotech is more favorable than Microbix Biosystems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
3.00
Microbix Biosystems
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

1.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 0.4% of Microbix Biosystems shares are owned by institutional investors. 3.8% of Oncolytics Biotech shares are owned by insiders. Comparatively, 14.0% of Microbix Biosystems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oncolytics Biotech's average media sentiment score of 0.39 beat Microbix Biosystems' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Oncolytics Biotech Neutral
Microbix Biosystems Neutral

Microbix Biosystems has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/A-C$27.66M-C$0.36-3.96
Microbix BiosystemsC$24.42M1.24C$3.39MC$0.038.76

Oncolytics Biotech has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, Microbix Biosystems has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.

Summary

Microbix Biosystems beats Oncolytics Biotech on 8 of the 14 factors compared between the two stocks.

Get Microbix Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

MetricMicrobix BiosystemsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$30.29MC$137.16MC$5.75BC$6.37B
Dividend Yield2.30%3.74%4.40%6.72%
P/E Ratio8.763.8731.3073.11
Price / Sales1.244,057.33432.981,702.26
Price / Cash4.1313.1937.7383.29
Price / Book1.1146.309.534.91
Net IncomeC$3.39M-C$90.99MC$3.26BC$301.20M
7 Day Performance-6.12%0.61%2.13%1.35%
1 Month Performance-22.03%3.70%2.80%1.88%
1 Year Performance-35.21%205.89%30.68%27.39%

Microbix Biosystems Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
Microbix Biosystems
N/AC$0.23
-2.1%
N/A-36.1%C$30.29MC$24.42M8.76N/A
ONC
Oncolytics Biotech
1.6556 of 5 stars
C$1.36
-2.9%
C$3.50
+157.4%
+9.2%C$104.82MN/A-3.7929Gap Up
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%
N/A+0.0%C$102.38MN/A0.00N/AHigh Trading Volume
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/A0.00N/A
NVH
Novoheart
N/AC$0.53
+1.9%
N/A+0.0%C$99.98MC$423.50K-13.95N/A
IGX
IntelGenx Technologies
N/AC$0.58
+1.8%
N/A+0.0%C$87.32MC$1.75M-7.442,050Gap Up
MDNA
Medicenna Therapeutics
N/AC$1.07
-1.8%
N/A-47.9%C$80.05MC$4.87K-2.9520
HBP
Helix BioPharma
N/AC$1.35
-2.2%
N/A+17.4%C$71.58MN/A-1.429News Coverage
Gap Down
PDP
Pediapharm
N/AC$0.30
+1.7%
N/A+0.0%C$66.36MC$11.16M-4.11N/A
COV
Covalon Technologies
N/AC$2.42
-16.0%
N/A-23.8%C$66.30MC$27.87M27.78N/ANews Coverage
Gap Up
APS
Aptose Biosciences
N/AC$1.53
-11.6%
N/A-90.4%C$65.88MN/A-0.3031News Coverage
Gap Up

Related Companies and Tools


This page (TSE:MBX) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners